Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).Jennifer S. LoCoco, Chris Karlovich, Robin Harrington et al.|Journal of Clinical Oncology|2023Cited by 2
Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).Chris Karlovich, P. Mickey Williams, Jennifer L. Silhavy et al.|Journal of Clinical Oncology|2023Cited by 1
Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results.Robin Harrington, Chris Karlovich, Amanda Peach et al.|Journal of Clinical Oncology|2022Cited by 0